Y. R. Cao

This study characterizes the antigenic properties and infectivity of the SARS-CoV-2 BA.2.86 variant, finding it evades immune responses but has reduced infectivity compared to previous variants.

This study shows that convergent evolution of SARS-CoV-2 XBB lineages at RBD positions 455-456 synergistically enhances antibody evasion and ACE2 binding through epistatic interactions.

This study shows XBB.1.5 has higher ACE2 binding and moderate antibody evasion, contributing to its increased transmissibility compared to other variants.

The paper assesses the protective effect of neutralizing antibodies from prior Omicron BA.5 infection against symptomatic reinfection with BA.5, BF.7, CH.1.1, and XBB.1.5 subvariants, finding a strong correlation between antibody titers and reduced reinfection risk.

The paper identifies a potent and broad sarbecovirus-neutralizing antibody cocktail, SA55+SA58, from SARS convalescents to combat Omicron variants and other fast-evolving viruses.

This study investigates antibody evasion by SARS-CoV-2 Omicron sublineages BA.2.12.1, BA.4, and BA.5 against plasma from vaccination and BA.1 infection, showing increased neutralization escape.

The paper characterizes structural and functional changes in the SARS-CoV-2 Omicron variant's Spike protein, identifying new immune escape sites and providing insights for vaccine development.

This study identifies how Omicron evades neutralizing antibodies by analyzing mutations and their effects on different epitope groups, showing over 85% of tested antibodies are escaped.

This study identifies two potent monoclonal antibodies against the B.1.351 variant and shows their efficacy against other variants, suggesting their use as an antibody cocktail.